Latest news with #Arrowhead
Asharq Al-Awsat
3 days ago
- Asharq Al-Awsat
Arrowhead…Remembering India's Iconic Crocodile-Hunting Tigress
Indian wildlife photographer Sachin Rai still remembers tigress 'Arrowhead' pouncing on a crocodile and tearing away its leathery flesh with her teeth. Rai had been photographing the iconic tigress in western Rajasthan state's Ranthambore National Park since she was a cub, according to BBC. Last week, Arrowhead, also known as T-84, died at the age of 11 near a stretch of lakes in the scenic park, the very territory she had gloriously ruled over in her prime. Her death, caused by an illness, was mourned by hundreds of wildlife enthusiasts, photographers and tour guides who had flocked to the park to get a glimpse of her. Arrowhead's legendary status comes partly from her lineage; she is the daughter of Krishna and granddaughter of Machli - majestic tigresses who, once upon a time, dominated vast home ranges in Ranthambore with ferocity. They were also skilled crocodile-killers, known to incapacitate the massive creatures by crushing their skulls in their powerful jaws. Rai said that Arrowhead - named such by another wildlife photographer after the distinct arrow-shaped stripes on her cheek - took to killing crocodiles after her health began failing her. 'But even though she was weak and frail, the crocodiles were no match for her,' Rai said. Her kills earned her the nickname 'crocodile-hunter' by her fans, he added. In fact, she killed a crocodile just days before her death. Though graceful and fierce, Arrowhead had a difficult life, Rai said. Arrowhead gave birth to four litters in her lifetime, but not all of her children survived. She grew weak after developing a tumor and park officials would have to bring her food when she couldn't hunt for days. However, this was stopped after some of her cubs attacked and killed people.
Indian Express
4 days ago
- General
- Indian Express
Famed Ranthambore tigress Arrowhead laid to rest, IFS officer says she ‘strengthened gene pools and rewrote conservation'
Arrowhead, one of the most photographed tigresses who once ruled Rajasthan's Ranthambore National Park, succumbed to a brain tumour on June 19. Her death came hours after her daughter was relocated to another tiger reserve. Also known as Tigress T-84, she is the granddaughter of the legendary 'Machali,' the most photographed tigress. As Arrowhead was laid to rest, Parveen Kaswan, an IFS officer, shared a heartwarming post. 'The famous arrowhead tigress from Ranthambore was given last rites, one of the most photographed tigress. Carried bloodline of Ranthambhore. She raised cubs that helped repopulate parts of Ranthambhore and other tiger reserves. Strengthened gene pools and rewrote conservation,' Kaswan wrote. Along with the post, Kaswan also shared a picture of the final rites of the tigress performed by forest officials. See here: The famous arrowhead tigress from Ranthambore was given last rites, one of the most photographed tigress. Carried bloodline of Ranthambhore. She raised cubs that helped repopulate parts of Ranthambhore and other tiger reserves. Strengthened gene pools and rewrote conservation. — Parveen Kaswan, IFS (@ParveenKaswan) June 24, 2025 According to the official website of Ranthambore National Park, in February 2018, Arrowhead gave birth to her first litter of three cubs, but they disappeared just days after their birth. She then gave birth again in January 2019 to two cubs, T-124, Riddhi; and T-125, Siddhi, who went on to become notable young tigresses themselves. In July 2021, Arrowhead delivered her third litter, again comprising three cubs, but they also disappeared shortly after birth. Her fourth and final litter arrived on July 25, 2023, with another set of three cubs. 'Arrowhead inherited a rich legacy from her legendary bloodline. She got her bravery from her grandmother, Machli. Her calm and composed demeanour was from her mother, T-19, also known as the Jhalra Female and a wild charm that was her own,' the website noted. 'True to her name, she has a distinctive arrow-shaped mark on her left cheek, similar to her grandmother's. Arrowhead was born from the mating of T-19 and T-28, a Star Male, continuing a royal tiger lineage,' the website added.
BBC News
4 days ago
- Entertainment
- BBC News
Arrowhead: Remembering India's iconic crocodile-hunting tigress
Indian wildlife photographer Sachin Rai still remembers tigress "Arrowhead" pouncing on a crocodile and tearing away its leathery flesh with her Rai had been photographing the iconic tigress in western Rajasthan state's Ranthambore national park since she was a week, Arrowhead, also known as T-84, died at the age of 11 near a stretch of lakes in the scenic park, the very territory she had gloriously ruled over in her death, caused by an illness, was mourned by hundreds of wildlife enthusiasts, photographers and tour guides who had flocked to the park to get a glimpse of legendary status comes partly from her lineage; she is the daughter of Krishna and granddaughter of Machli - majestic tigresses who, once upon a time, dominated vast home ranges in Ranthambore with ferocity. They were also skilled crocodile-killers, known to incapacitate the massive creatures by crushing their skulls in their powerful jaws. Mr Rai says that Arrowhead - named such by another wildlife photographer after the distinct arrow-shaped stripes on her cheek - took to killing crocodiles after her health began failing her."But even though she was weak and frail, the crocodiles were no match for her," Mr Rai kills earned her the nickname "crocodile-hunter" by her fans, he adds. In fact, she killed a crocodile just days before her graceful and fierce, Arrowhead had a difficult life, Mr Rai says. She was chased out of her territory by her own daughter, Riddhi, and had to mate multiple times in order to find a place she could call home. (A male tiger shares his territory with his mate, offering her a space to bring up their cubs.) Arrowhead gave birth to four litters in her lifetime, but not all of her children grew weak after developing a tumour and park official's would have to bring her food when she couldn't hunt for days. However, this was stopped after some of her cubs attacked and killed Rai, who was around when Arrowhead was nearing her end, says that it was heart-breaking to see a powerful, majestic creature become so weak and powerless."I saw her struggling to walk. Every step seemed like an effort and she kept falling down," he Arrowhead ventured into her daughter Riddhi's territory - which was once her own - in her last days. "Riddhi didn't put up a fight. She just gave her mother space to lie down and rest," Mr Rai says, tearing up. Follow BBC News India on Instagram, YouTube, Twitter and Facebook.
India Today
5 days ago
- General
- India Today
Farewell Arrowhead: The queen of Rajbagh leaves behind a roaring legacy
To spot Arrowhead one more time in the wild is merely a dream now. The queen breathed her last on June 19 near Jogi Mahal in a long battle with bone cancer and a brain tumour, Arrowhead's magnificent journey concluded at the age of 11. Following a postmortem, she was cremated at Rajbhag in the Ranthambore Tiger Reserve, as the Forest department and her fans bid her a final, sorrowful also known as Tigress T-84, got her name from the identifiable arrow-shaped mark on her face. She was born to 'Krishna' and 'Star' Male T-28, along with her siblings 'Lightning' and 'Pacman', and was first sighted in year 2014. She reigned over Zones 2, 3, and 4 of the Ranthambore Tiger Reserve, and was often seen around Rajbagh Lake—a territory once ruled by her mother, Krishna, and grandmother, Machhli. Without a doubt, she was one of the most photographed tigers of the final walk, captured on camera near Padma Talab on June 17th by nature photographer Sachin Rai, was heartbreaking (probably her last video). With a sunken belly and visible ribs, it was clear her end was near, a sentiment Rai himself expressed on Instagram. advertisement View this post on Instagram A post shared by Sachin Rai (@sachin_rai_photography)Speaking to India Today, Rai described the heartbreaking scene: "I knew she wasn't well. I had seen her couple of months ago. But to see her so frail and fragile, having lost almost all her weight—she was only skin and bones—it was gut-wrenching just watching her struggle to get up and walk."Sachin Rai, who documented Arrowhead's life from a tiny cub to her final days, shared a poignant memory of her. "Three years ago, I witnessed her first interaction with a young male tiger, T120," he recounted. "She eventually mated with him many months later. However, their initial encounter was fascinating to observe. She was both cautious and vibrant, unsure of who he was or if he'd stay. She crouched, snarled, and displayed submissive behavior. It was an incredible experience to watch her."Though illness and weakness ravaged her body, they never broke Arrowhead's spirit. This was incredibly evident during one of her last hunts when she remarkably attempted to take down a crocodile, much like her legendary grandmother, Machhli. Rai described this as "fascinating behavior." He added, "I guess her hunger and instinct took over her logic, and she decided to go for the kill. And despite her extreme weakness, she incredibly managed to kill the crocodile." Arrowhead's passing truly marks the end of an era, but her bloodline lives on. She was a gracious, strong mother who has produced four litters during her life time. Among her offspring are Ranthambore's popular tigers, 'Riddhi', 'Siddhi'. While mother tigers typically raise and train their cubs in the wild, Arrowhead's illness sadly prevented her from doing so for her last litter, which included Kankati and her two queen departed for the happy hunting grounds mere hours after her last cub, Kankati, was safely relocated to another tiger reserve in the state, almost as if Arrowhead had waited to ensure her cub's safe Arrowhead. You'll forever live in the jungle of our hearts.- Ends
Business Wire
5 days ago
- Business
- Business Wire
Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in SHASTA-3, SHASTA-4, and MUIR-3, the company's global Phase 3 clinical studies designed to support regulatory submissions for marketing approval of investigational plozasiran in the treatment of severe hypertriglyceridemia. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. The company previously submitted a New Drug Application (NDA) for plozasiran based on positive Phase 3 PALISADE study results in patients with familial chylomicronemia syndrome, which the U.S. FDA has accepted with a Prescription Drug User Fee Act (PDUFA) action date set for November 18, 2025. Arrowhead anticipates completing the primary portion of these studies in mid-2026 with topline data expected shortly thereafter and planned submissions for regulatory review and potential approval to follow. 'Completion of enrollment for the SHASTA-3, SHASTA-4, and MUIR-3 studies represent important milestones for plozasiran,' said Bruce Given, M.D., Chief Medical Scientist at Arrowhead. 'These studies bring us closer to generating the datasets needed to support potential global regulatory submissions for plozasiran as a treatment for severe hypertriglyceridemia, pending positive results. With a primary endpoint focused on triglyceride reduction at 12 months, we remain on track for study completion by mid-2026. Arrowhead's clinical development, clinical operations, and regulatory teams continue to execute complex global clinical studies with speed and precision. We owe the entire team involved a debt of gratitude for efficiently initiating these studies in 24 countries and enrolling approximately 2,200 patients. We're grateful to the investigators, caregivers, and patients for participating in these clinical studies, and we thank them for their trust in Arrowhead and in plozasiran.' About Severe Hypertriglyceridemia Severe hypertriglyceridemia (SHTG) is characterized by triglyceride (TG) levels greater than 500 mg/dL, with the most severe form being familial chylomicronemia syndrome (FCS) where TGs typically exceed 880 mg/dL. SHTG significantly increases the risk of acute pancreatitis (AP), which can often include recurrent attacks requiring repeat hospital admissions and worsening outcomes. AP risk is proportional to the number, characteristics, and concentration of triglyceride rich lipoproteins (TRLs), particularly chylomicrons, and increases as TGs rise. Elevated TGs can also increase the risk of atherosclerotic cardiovascular disease (ASCVD). Limited treatment options exist to sustainably reduce TGs below guideline directed risk thresholds. About SHASTA-3 and SHASTA-4 Phase 3 Studies SHASTA-3 (NCT06347003) and SHASTA-4 (NCT06347016) are double-blind, placebo-controlled, Phase 3 studies to evaluate the efficacy and safety of plozasiran in adults with severe hypertriglyceridemia. Between the two studies, approximately 750 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension. About MUIR-3 Phase 3 Study MUIR-3 (NCT06347133) is a double-blind, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of plozasiran in adults with hypertriglyceridemia (TGs greater than 150 mg/dL and less than 500 mg/dL). Approximately 1,450 participants were randomized to receive 4 doses (once every 3 months) of 25 mg plozasiran or placebo. The primary endpoint is percent change in fasting serum triglyceride levels from baseline to month 12 compared to placebo. About Plozasiran Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a component of triglyceride rich lipoproteins (TRLs) and a key regulator of triglyceride metabolism. APOC3 increases triglyceride levels in the blood by inhibiting breakdown of TRLs by lipoprotein lipase and uptake of TRL remnants by receptors in the liver. The goal of treatment with plozasiran is to reduce the level of APOC3, thereby reducing triglycerides and restoring lipids to more normal levels. In multiple clinical studies, investigational plozasiran has demonstrated reductions in triglycerides and multiple atherogenic lipoproteins in patients with familial chylomicronemia syndrome (FCS), severe hypertriglyceridemia (SHTG), and mixed hyperlipidemia. Plozasiran has been generally well tolerated to date with treatment emergent adverse events reported that generally reflect the comorbidities and underlying conditions of the study populations. Across clinical studies and study populations, the most frequently reported treatment emergent adverse events for the 25 mg dose that is proposed for marketing approval were COVID-19, upper respiratory tract infection, headache, Type 2 diabetes mellitus, and abdominal pain. Plozasiran is being investigated in the SUMMIT program of clinical studies, including the PALISADE Phase 3 study in patients with FCS, the SHASTA studies in patients with SHTG, and the MUIR studies in patients with mixed hyperlipidemia. Plozasiran in the treatment of patients with FCS has been granted Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation by the U.S. Food and Drug Administration and Orphan Medicinal Product Designation by the European Medicines Agency. Investigational plozasiran has been submitted for marketing authorization in treatment of FCS to multiple global regulatory authorities but has not been reviewed or approved to treat any disease. About Arrowhead Pharmaceuticals, Inc. Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit Safe Harbor Statement under the Private Securities Litigation Reform Act: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as 'may,' 'might,' 'will,' 'expect,' 'believe,' 'anticipate,' 'goal,' 'endeavor,' 'strive,' 'hope,' 'intend,' 'plan,' 'project,' 'could,' 'estimate,' 'potential,' 'target,' 'forecast' or 'continue' or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding regulatory approval for and commercial launch of plozasiran; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances. Source: Arrowhead Pharmaceuticals, Inc.
